These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 22641830)
1. Drug companies and publishers set out 10 steps to enhance credibility of industry sponsored trials. Roehr B BMJ; 2012 May; 344():e3767. PubMed ID: 22641830 [No Abstract] [Full Text] [Related]
2. Independent medical research. van der Meer JW; de Gier AM; van Swaaij WP; Katan MB Neth J Med; 2007 Apr; 65(4):124-6. PubMed ID: 17452759 [No Abstract] [Full Text] [Related]
3. Comments on 'The potential for bias in the reporting of industry sponsored clinical trials' by Stephen Pyke et al. and 'Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry sponsored clinical trials' by James Matcham et al. Pharmaceutical Statistics. Campbell MJ Pharm Stat; 2011; 10(1):80-1. PubMed ID: 21275038 [No Abstract] [Full Text] [Related]
4. Note from the editor. Freedman R Am J Psychiatry; 2010 Nov; 167(11):1407. PubMed ID: 21041255 [No Abstract] [Full Text] [Related]
5. Falling out with pharma. Whitehead S Lancet; 2013 Mar; 381(9872):1096-7. PubMed ID: 23540851 [No Abstract] [Full Text] [Related]
6. Industry sponsored research. Klotz LH Can J Urol; 2004 Aug; 11(4):2312-3. PubMed ID: 15380051 [No Abstract] [Full Text] [Related]
7. The potential for bias in reporting of industry-sponsored clinical trials. Pyke S; Julious SA; Day S; O'Kelly M; Todd S; Matcham J; Seldrup J Pharm Stat; 2011; 10(1):74-9. PubMed ID: 21275037 [TBL] [Abstract][Full Text] [Related]
8. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials. Matcham J; Julious S; Pyke S; O'Kelly M; Todd S; Seldrup J; Day S Pharm Stat; 2011; 10(1):70-3. PubMed ID: 20187020 [TBL] [Abstract][Full Text] [Related]
9. Managing physician financial conflicts of interest in clinical trials conducted in the private practice setting. Williams KM Food Drug Law J; 2004; 59(1):45-77. PubMed ID: 15190925 [No Abstract] [Full Text] [Related]
10. The sins of ghostwriting. Somberg JC Am J Ther; 2008; 15(4):297-8. PubMed ID: 18645328 [No Abstract] [Full Text] [Related]
11. Expedited industry-sponsored translational research: a seductive but hazardous cocktail? Marks JH Am J Bioeth; 2008 Mar; 8(3):56-8; discussion W1-3. PubMed ID: 18570106 [No Abstract] [Full Text] [Related]
12. 'Interests' in medicine and the inadequacy of disclosure. Kerridge I Aust N Z J Psychiatry; 2012 Jun; 46(6):501-3. PubMed ID: 22679203 [No Abstract] [Full Text] [Related]
13. The corporate coauthor. Fugh-Berman A J Gen Intern Med; 2005 Jun; 20(6):546-8. PubMed ID: 15987332 [TBL] [Abstract][Full Text] [Related]
15. Ethical issues in the relationships involving medicine and industry. Thomas PS; Tan KS; Yates DH Intern Med J; 2005 Dec; 35(12):732. PubMed ID: 16313554 [No Abstract] [Full Text] [Related]
16. In the dark: drug companies should be forced to publish all the results of clinical trials. Chalmers I New Sci; 2004 Mar 6-12; 181(2437):19. PubMed ID: 15139350 [No Abstract] [Full Text] [Related]
17. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. Lachin JM Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730 [TBL] [Abstract][Full Text] [Related]
18. "Good Publication Practice for Pharmaceutical Companies": where are we now? Wager E MedGenMed; 2005 Apr; 7(2):6. PubMed ID: 16369385 [TBL] [Abstract][Full Text] [Related]
19. [Knowledge on feet of clay]. Dahlqvist R Lakartidningen; 2008 May 7-13; 105(19):1405-6. PubMed ID: 18574980 [No Abstract] [Full Text] [Related]
20. Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? No. Lawton V BMJ; 2009 Nov; 339():b4953. PubMed ID: 19946144 [No Abstract] [Full Text] [Related] [Next] [New Search]